Up to 85% of the human proteome is considered “undruggable,” with proteins that lack the pockets where traditional therapeutics can bind. But that barrier is beginning to shift.

A new wave of biotech companies is bringing forward breakthrough technologies designed to target the most elusive proteins—opening the door to therapies once thought impossible. In this episode, we explore the science, innovation, and opportunities behind cracking the code of the so-called “undruggable” proteome.